Dark data not only generates unnecessary costs, but also increases risks and the potential for losses. Here's what business ...
Cardiff, Inc. today released findings from its latest industry report, "The Economic Advantage of Speed-First Capital." ...
Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
A rise of 3.2% in CPI inflation in the 12 months to November undershoots almost all expectations ...
Discover a 2026 S&P 500 outlook with three scenario analyses, focusing on AI investments and consumer trends. Click for my ...
Policies such as the head tax threaten to make Chicago’s fiscal problems worse by discouraging job creation and economic ...
(11/15 participants) improved on the Overall Cutaneous Venous Malformations Investigator Global Assessment (Overall ...
The A to Z of over 100 electric vehicles on the market in terms of price, range and the EV's ability to provide external ...
Africans abroad send home about $91 billion annually, but high transaction costs and the dominance of informal channels limit ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...
GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...
US FDA approves GSK’s Exdensur for the treatment of severe asthma: London, UK Thursday, December 18, 2025, 11:00 Hrs [IST] GSK plc announced that the US Food and Drug Administra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results